

December 21, 2022

To,
The Manager,
Dept. of Corporate Services,
BSE Limited,
Phiroze Jeejeebhoy Towers,
Dalal Street, Mumbai - 400001

Dear Sir/Madam,

Subject : Outcome of the Board Meeting
Reference : Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015
Scrip : 511509

Dear Sir/Madam,

With reference to the above cited subject and our letter dated December 12, 2022, we bring to your kind notice that the Board of Directors of the Company at their meeting held today, i.e. **Wednesday, December 21, 2022**, *inter-alia*, transacted the following business:

1. Approval for engagement/appointment of Consultants or intermediaries for the proposed issuance of equity shares/warrants by way of a preferential allotment, in accordance with the provisions of the SEBI (Issue of Capital and Disclosure Requirements) Regulations, 2018 and the Companies Act, 2013, as amended, subject to such regulatory/ statutory approvals as may be required.

The Company shall intimate to the stock exchange the date of Board Meeting scheduled to be held to consider the issuance of equity shares/warrants by way of a preferential allotment on recommendation of the engaged Consultants/intermediaries as required under SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

The meeting commenced at 06.00 PM and concluded at 06.30 PM.

This is for your information and records.

Thanking you,

Yours faithfully,

For Vivo Bio Tech Limited

Jyotika Aasat
Company Secretary